PMVP net incomeQ2 2026-$18.09M
PMVP net income was -$18.09M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$21.21M a year earlier. For the full fiscal 2025 it was -$77.74M, compared with -$58.71M in fiscal 2024.
PMV Pharmaceuticals Inc. (PMVP) financials
For the twelve months ended Jun 30, 2026, PMV Pharmaceuticals Inc. reported -$75.22M of net income.
- Net income, TTM
- -$75.22M
- Free cash flow, TTM
- -$71.28M
- EPS, diluted, TTM
- -$1.41
- Cash
- $12.47M
- Market cap
- $94.4M
FY2018FY2025
FY2018FY2025
PMVP revenue and earnings growth
PMVP EPSQ2 2026-$0.34
PMVP diluted EPS was -$0.34 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.41 a year earlier. For the full fiscal 2025 it was -$1.48, compared with -$1.14 in fiscal 2024.
PMVP free cash flowQ2 2026-$14.58M
PMVP free cash flow was -$14.58M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$18.31M a year earlier. For the full fiscal 2025 it was -$73.61M, compared with -$51.94M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Research and development | $69.88M | $58.53M | $55.88M | $51.99M | $36.49M | $23.93M | $20.76M | $13.85M |
| Selling, general and admin | $16.33M | $26.92M | $24.25M | $25.05M | $21.80M | $11.01M | $5.88M | $5.04M |
| Operating income | -$86.21M | -$85.45M | -$80.13M | -$77.04M | -$58.29M | -$34.94M | -$26.64M | -$18.89M |
| Pre-tax income | -$79.91M | -$74.81M | -$68.96M | -$73.33M | -$57.82M | -$34.43M | -$25.34M | -$17.54M |
| Income tax | -$2.17M | -$16.10M | $2.0K | -$9.0K | $23.0K | $6.0K | $8.0K | $3.0K |
| Net income | -$77.74M | -$58.71M | -$68.96M | -$73.32M | -$57.85M | -$34.44M | -$25.35M | -$17.54M |
| EPS, basic | -$1.48 | -$1.14 | -$1.44 | -$1.61 | -$1.28 | -$2.40 | -$8.35 | -$5.82 |
| EPS, diluted | -$1.48 | -$1.14 | -$1.44 | -$1.61 | -$1.28 | -$2.40 | -$8.35 | -$5.82 |
| Diluted shares | 52.5M | 51.6M | 48.0M | 45.6M | 45.1M | 14.4M | 3.0M | 3.0M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $37.98M | $40.88M | $37.71M | $108.30M | $172.47M | $361.42M | $73.28M | - |
| Short-term investments | $74.96M | $128.58M | $165.35M | $132.76M | $124.70M | - | - | - |
| Current assets | $115.23M | $175.66M | $207.41M | $247.01M | $301.29M | $364.76M | $102.09M | - |
| Total assets | $116.56M | $191.29M | $252.15M | $270.31M | $331.57M | $365.53M | $103.03M | - |
| Current liabilities | $11.41M | $14.37M | $14.03M | $10.83M | $12.22M | $6.41M | $4.52M | - |
| Total liabilities | $11.85M | $15.21M | $26.46M | $24.28M | $23.01M | $6.41M | $4.57M | - |
| Shareholders' equity | $104.71M | $176.08M | $225.69M | $246.03M | $308.56M | $359.12M | -$70.47M | -$46.14M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$73.58M | -$51.28M | -$55.66M | -$63.76M | -$46.57M | -$32.74M | -$22.07M | -$15.18M |
| Capital expenditures | $29.0K | $655.0K | $962.0K | $7.98M | $1.35M | $148.0K | $109.0K | $452.0K |
| Free cash flow | -$73.61M | -$51.94M | -$56.62M | -$71.74M | -$47.92M | -$32.89M | -$22.17M | -$15.63M |
| Investing cash flow | $70.17M | $53.35M | -$50.55M | -$1.37M | -$143.58M | $27.91M | $3.23M | $21.69M |
| Financing cash flow | $505.0K | $313.0K | $35.58M | $958.0K | $2.02M | $292.97M | $61.80M | - |
| Stock-based compensation | $5.92M | $8.87M | $12.38M | $10.20M | $5.34M | $1.93M | $908.0K | $1.08M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Return on equity | -74.2% | -33.3% | -30.6% | -29.8% | -18.7% | -9.6% | - | - |
| Return on assets | -66.7% | -30.7% | -27.3% | -27.1% | -17.4% | -9.4% | -24.6% | - |
| Current ratio | 10.09 | 12.22 | 14.78 | 22.80 | 24.66 | 56.90 | 22.57 | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $14.68M | $15.33M | $15.83M | $18.21M | $18.40M | $17.44M | $13.77M | $16.95M | $14.63M | $13.19M | $13.38M | $13.59M |
| Selling, general and admin | $4.21M | $3.69M | $3.42M | $4.31M | $4.48M | $4.12M | $11.40M | $4.94M | $5.54M | $5.04M | $5.52M | $6.04M |
| Operating income | -$18.88M | -$19.02M | -$19.24M | -$22.52M | -$22.88M | -$21.56M | -$25.17M | -$21.89M | -$20.17M | -$18.22M | -$18.90M | -$19.63M |
| Pre-tax income | -$18.08M | -$18.04M | -$18.01M | -$21.07M | -$21.20M | -$19.63M | -$23.00M | -$19.15M | -$17.39M | -$15.27M | -$15.76M | -$16.64M |
| Income tax | $3.0K | $0 | $26.0K | -$6.0K | $5.0K | -$2.20M | $0 | $74.0K | -$16.17M | $0 | -$1.0K | -$1.0K |
| Net income | -$18.09M | -$18.04M | -$18.04M | -$21.06M | -$21.21M | -$17.44M | -$23.00M | -$19.23M | -$1.21M | -$15.27M | -$15.76M | -$16.64M |
| EPS, basic | -$0.34 | -$0.34 | -$0.33 | -$0.40 | -$0.41 | -$0.34 | -$0.45 | -$0.37 | -$0.02 | -$0.30 | -$0.30 | -$0.34 |
| EPS, diluted | -$0.34 | -$0.34 | -$0.33 | -$0.40 | -$0.41 | -$0.34 | -$0.45 | -$0.37 | -$0.02 | -$0.30 | -$0.30 | -$0.34 |
| Diluted shares | 53.4M | 53.3M | - | 53.0M | 52.0M | 52.0M | - | 51.6M | 51.5M | 51.4M | - | 49.0M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $12.47M | $39.13M | $37.98M | $36.34M | $44.13M | $51.34M | $40.88M | $48.81M | $48.53M | $47.65M | $37.71M | $52.06M |
| Short-term investments | $66.96M | $54.42M | $74.96M | $92.91M | $98.15M | $109.05M | $128.58M | $134.03M | $164.39M | $150.28M | $165.35M | $149.86M |
| Current assets | $81.41M | $95.78M | $115.23M | $132.45M | $145.31M | $163.50M | $175.66M | $189.62M | $218.79M | $202.46M | $207.41M | $205.30M |
| Total assets | $82.07M | $96.56M | $116.56M | $133.84M | $152.85M | $170.61M | $191.29M | $223.50M | $237.54M | $236.88M | $252.15M | $261.03M |
| Current liabilities | $10.57M | $8.60M | $11.41M | $12.30M | $11.61M | $9.76M | $14.37M | $13.56M | $11.38M | $12.06M | $14.03M | $10.72M |
| Total liabilities | $10.57M | $8.60M | $11.85M | $12.85M | $12.25M | $10.50M | $15.21M | $25.59M | $23.22M | $24.20M | $26.46M | $23.41M |
| Shareholders' equity | $71.50M | $87.97M | $104.71M | $121.00M | $140.60M | $160.11M | $176.08M | $197.91M | $214.32M | $212.68M | $225.69M | $237.61M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$14.58M | -$19.68M | -$17.19M | -$19.82M | -$18.30M | -$18.27M | -$16.66M | -$16.84M | -$1.60M | -$16.18M | -$12.09M | -$15.66M |
| Capital expenditures | $0 | $0 | $15.0K | -$1.0K | $11.0K | $4.0K | $56.0K | $1.0K | $4.0K | $594.0K | $197.0K | $44.0K |
| Free cash flow | -$14.58M | -$19.68M | -$17.20M | -$19.82M | -$18.31M | -$18.27M | -$16.72M | -$16.84M | -$1.60M | -$16.78M | -$12.28M | -$15.70M |
| Investing cash flow | -$12.23M | $20.82M | $18.44M | $12.03M | $10.99M | $28.71M | $7.74M | $17.12M | $2.32M | $26.17M | -$2.59M | -$33.64M |
| Financing cash flow | $143.0K | $0 | $392.0K | $0 | $103.0K | $10.0K | $172.0K | $0 | $141.0K | $0 | $288.0K | $33.15M |
| Stock-based compensation | $1.54M | $1.39M | $1.36M | $1.38M | $1.67M | $1.51M | $1.27M | $2.22M | $2.77M | $2.61M | $2.97M | $3.32M |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 7.70 | 11.14 | 10.09 | 10.76 | 12.52 | 16.75 | 12.22 | 13.98 | 19.22 | 16.79 | 14.78 | 19.16 |
Source: XBRL data PMV Pharmaceuticals Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
PMVP peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| PMVP | - | - | -$75.22M | - | $94.4M |
| RAIN | - | - | -$11.76M | - | $6.4M |
| ZNTL | $0 | -100.0% | -$137.06M | - | $164.7M |
| ERAS | - | - | -$287.22M | - | $5.46B |
| RVMD | $0 | - | -$1.13B | - | $43.29B |
| CGEM | - | - | -$204.69M | - | $754.9M |
PMVP FAQ
6 questionsIs PMVP profitable?
No. PMV Pharmaceuticals Inc. reported a net loss of $75.22M for the twelve months ended Jun 30, 2026.How much cash and debt does PMVP have?
PMV Pharmaceuticals Inc. reported $12.47M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is PMVP free cash flow?
PMV Pharmaceuticals Inc. generated -$71.28M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$71.27M less capital expenditures.What is PMVP earnings per share?
Diluted earnings per share were -$1.41 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did PMVP last report financial results?
The latest statements here come from PMV Pharmaceuticals Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.Where does this PMVP financial data come from?
Quantisnow builds these statements from the structured XBRL data PMV Pharmaceuticals Inc. files with the SEC. It is provided for information only and is not investment advice.